Evelo Biosciences, Inc. (EVLO)
OTCMKTS
· Delayed Price · Currency is USD
0.0004
-0.0001 (-20.00%)
Dec 24, 2024, 11:08 AM EST
Evelo Biosciences Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | 2017 - 2016 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '23 Sep 30, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | Dec '18 Dec 31, 2018 | 2017 - 2016 |
| Cash & Equivalents | 17.26 | 47.94 | 68.44 | 68.86 | 77.83 | 93.1 | Upgrade
|
| Short-Term Investments | - | - | - | - | - | 54.82 | Upgrade
|
| Cash & Short-Term Investments | 17.26 | 47.94 | 68.44 | 68.86 | 77.83 | 147.92 | Upgrade
|
| Cash Growth | -75.00% | -29.95% | -0.60% | -11.53% | -47.38% | 286.76% | Upgrade
|
| Prepaid Expenses | 1.67 | 3.63 | 2.59 | 1.86 | 3.18 | 3.7 | Upgrade
|
| Restricted Cash | - | - | - | 0.26 | - | - | Upgrade
|
| Total Current Assets | 18.94 | 51.57 | 71.03 | 70.98 | 81.01 | 151.62 | Upgrade
|
| Property, Plant & Equipment | 0.89 | 11.71 | 15.53 | 18.24 | 8.34 | 6.93 | Upgrade
|
| Other Long-Term Assets | 0.8 | 1.16 | 1.31 | 1.42 | 1.57 | 1.32 | Upgrade
|
| Total Assets | 20.63 | 64.44 | 87.87 | 90.64 | 90.92 | 159.87 | Upgrade
|
| Accounts Payable | 0.53 | 1.76 | 1.6 | 1.44 | 0.62 | 1.52 | Upgrade
|
| Accrued Expenses | 4.55 | 7.95 | 13.07 | 16.25 | 8.76 | 4.97 | Upgrade
|
| Current Portion of Leases | - | 2.26 | 1.95 | 1.67 | - | - | Upgrade
|
| Other Current Liabilities | 0.74 | 0.43 | 0.74 | 0.46 | 0.37 | 2.75 | Upgrade
|
| Total Current Liabilities | 39.76 | 12.4 | 17.36 | 19.83 | 9.74 | 9.24 | Upgrade
|
| Long-Term Debt | - | 43.61 | 46.56 | 30.05 | 19.63 | 12.31 | Upgrade
|
| Long-Term Leases | - | 5.27 | 7.79 | 9.99 | - | - | Upgrade
|
| Long-Term Unearned Revenue | 7.5 | 7.5 | 7.5 | - | - | - | Upgrade
|
| Other Long-Term Liabilities | 0.07 | 0.66 | - | 0.28 | 1.35 | 1.38 | Upgrade
|
| Total Liabilities | 47.33 | 69.43 | 79.2 | 60.15 | 30.72 | 22.92 | Upgrade
|
| Common Stock | 0.02 | 0.11 | 0.05 | 0.05 | 0.03 | 0.03 | Upgrade
|
| Additional Paid-In Capital | 561.3 | 524.12 | 423.31 | 322.96 | 259.02 | 250.32 | Upgrade
|
| Retained Earnings | -588.03 | -529.22 | -414.7 | -292.52 | -198.85 | -113.38 | Upgrade
|
| Comprehensive Income & Other | - | - | - | - | - | -0.02 | Upgrade
|
| Total Common Equity | -26.71 | -4.99 | 8.67 | 30.49 | 60.2 | 136.95 | Upgrade
|
| Shareholders' Equity | -26.71 | -4.99 | 8.67 | 30.49 | 60.2 | 136.95 | Upgrade
|
| Total Liabilities & Equity | 20.63 | 64.44 | 87.87 | 90.64 | 90.92 | 159.87 | Upgrade
|
| Total Debt | 33.95 | 51.14 | 56.29 | 41.71 | 19.63 | 12.31 | Upgrade
|
| Net Cash (Debt) | -16.69 | -3.2 | 12.15 | 27.15 | 58.2 | 135.61 | Upgrade
|
| Net Cash Growth | - | - | -55.25% | -53.36% | -57.08% | 379.54% | Upgrade
|
| Net Cash Per Share | -1.95 | -0.73 | 4.59 | 13.75 | 36.34 | 124.01 | Upgrade
|
| Filing Date Shares Outstanding | 18.93 | 5.55 | 2.68 | 2.67 | 1.61 | 1.59 | Upgrade
|
| Total Common Shares Outstanding | 18.85 | 5.54 | 2.68 | 2.37 | 1.61 | 1.59 | Upgrade
|
| Working Capital | -20.83 | 39.18 | 53.66 | 51.15 | 71.27 | 142.39 | Upgrade
|
| Book Value Per Share | -1.42 | -0.90 | 3.24 | 12.84 | 37.42 | 86.06 | Upgrade
|
| Tangible Book Value | -26.71 | -4.99 | 8.67 | 30.49 | 60.2 | 136.95 | Upgrade
|
| Tangible Book Value Per Share | -1.42 | -0.90 | 3.24 | 12.84 | 37.42 | 86.06 | Upgrade
|
| Machinery | 2.88 | 10.9 | 10.78 | 9.89 | 8.44 | 6.04 | Upgrade
|
| Construction In Progress | 0.09 | 1.12 | 1.32 | 1.08 | 1.59 | 1.01 | Upgrade
|
| Leasehold Improvements | - | 2.16 | 2.16 | 2.16 | 2.01 | 1.82 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.